The Methodist Hospital Research Institute - search results

United States - English - NLM (National Library of Medicine)

ammonia n-13 injection

the methodist hospital research institute - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n 13 injection is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection. it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taking into account the importance of the drug to the mother. the safety and effectiveness of ammonia n 13 injection has been established in pediatric patients based on known metabolism of ammonia, radiation dosimetry in the pediatric population, and clinical studies in adults [see dosage and administration ( 2.4)].

United States - English - NLM (National Library of Medicine)

fludeoxyglucose f18 injection, solution

the methodist hospital research institute - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 0.3 ci in 1 ml - fludeoxyglucose f18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection usp crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiatio

Australia - English - Department of Health (Therapeutic Goods Administration)

evocide extra (pf-058) hospital grade disinfectant cleaner 500 ml, 750ml, 1l

novapharm research (australia) pty ltd - 9950 - disinfectant, hospital grade - other therapeutic

Australia - English - Department of Health (Therapeutic Goods Administration)

hpa480a patient trolley - stretcher, hospital

hospital products australia pty ltd - 35892 - stretcher, hospital - a mobile stretcher designed to fulfil several purposes e.g., for transportation permitting one attendant, nurse, physician or aide to transport a recumbent patient within a healthcare facility. this device may also be used as a treatment table in such areas as the emergency room, recovery room, and labour room. it may be also used as a bed in some intensive and specialized care units. during large scale disasters or catastrophes causing high patient census conditions, it can be pressed into service as a hospital bed. this device may be motorized and equipped with emergency equipment.